Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of the age of 2 years and older suffering from a tree pollen induced seasonal allergic rhinitis~Exclusion Criteria:~* Patients suffering from acute or chronic infections or inflammations~* Patients suffering from secondary modifications of the target organ with function impairment (emphysema, bronchiectasis)~* Patients suffering from severe and uncontrolled asthma~* Patients with a known severe autoimmune disease~* Patients with active malignant disease~* Patients requiring beta-blockers~* Patients having any contraindication for the use of adrenaline~* Patients with a hypersensitivity to the excipients of the drug

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ORALVAC COMPACT BÄUME (Type: None): This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).